Protease Inhibitor
Showing 1 - 25 of 8,115
COVID-19 Trial in Minneapolis (Shionogi Protease Inhibitor (S-217622), )
Recruiting
- COVID-19
- Shionogi Protease Inhibitor (S-217622)
- placebo
-
Minneapolis, MinnesotaUniversity of Minnesota
Jan 12, 2023
SLPI for Prostate Cancer
Recruiting
- Prostate Cancer
- Prostatic Neoplasm
- Secretory leukocyte protease inhibitor (SLPI) in prostate cancer
- +2 more
-
Florence, Tuscany, ItalyCareggi University Hospital
May 6, 2022
HIV Trial in Bangkok (generic single tablet TAF/FTC/DTG)
Active, not recruiting
- HIV
- generic single tablet TAF/FTC/DTG
-
Bangkok, Thailand
- +1 more
Mar 22, 2022
HIV-1 Infection Trial (Doravirine, Tenofovir, Lamivudine, Baseline regimen of ritonavir- or cobicistat-boosted protease
Active, not recruiting
- HIV-1 Infection
- Doravirine, Tenofovir, Lamivudine
- +4 more
- (no location specified)
Sep 2, 2022
Multiple Myeloma Trial in Tianjin (Anlotinib Hydrochloride Capsule)
Recruiting
- Multiple Myeloma
- Anlotinib Hydrochloride Capsule
-
Tianjin, Tianjin, ChinaInstituteHBDH
Sep 18, 2022
Covid19 Trial in South Africa, United States (Part A: Upamostat 200 mg, Part A: Upamostat 400 mg, Part A and B: Placebo)
Suspended
- Covid19
- Part A: Upamostat 200 mg
- +3 more
-
Cutler Bay, Florida
- +16 more
Aug 2, 2022
Hepatitis C, HIV Coinfection Trial in Aurora (TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF
Completed
- Hepatitis C
- HIV Coinfection
- TDF with a boosted protease inhibitor
- +2 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Jan 21, 2021
HIV I Infection, Adiposity Trial in Saint Louis (Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose
Recruiting
- HIV I Infection
- Adiposity
- Frequently sampled glucose tolerance testing
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Jun 15, 2022
HIV Trial in United States (Indinavir sulfate, Ritonavir, Amprenavir)
Completed
- HIV Infections
- Indinavir sulfate
- +5 more
-
Palo Alto, California
- +7 more
Oct 28, 2021
Stage III, IVa, or IVb Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx Trial in Philadelphia
Active, not recruiting
- Stage III, IVa, or IVb Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx
- Nelfinavir (Viracept®) 1250 mg
- FMISO
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jun 30, 2021
HIV Trial in United States (Indinavir sulfate, Ritonavir, Nelfinavir mesylate)
Completed
- HIV Infections
- Indinavir sulfate
- +3 more
-
San Francisco, California
- +14 more
Oct 27, 2021
Human Immunodeficiency Virus Type 1 Trial in Worldwide (D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF)
Completed
- Human Immunodeficiency Virus Type 1
- D/C/F/TAF
- +2 more
-
Phoenix, Arizona
- +81 more
Nov 25, 2021
Aging-related Inflammation in HIV-infected Patients Trial in Badalona (Raltegravir, PI-based regimen, Atorvastatin)
Completed
- Aging-related Inflammation in HIV-infected Patients
- Raltegravir
- +2 more
-
Badalona, Barcelona, SpainGermans Trias i Pujol Hospital
Oct 7, 2020
Advanced Solid Tumors Trial in United States (KSQ-4279, KSQ-4279 will be combined in separate cohorts, including combination
Recruiting
- Advanced Solid Tumors
- KSQ-4279
- KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
-
Boston, Massachusetts
- +4 more
Apr 5, 2022
HIV-1-infection, Antiretroviral Therapy Trial in Port-au-Prince (Continuation of boosted PI, B/F/TAF)
Not yet recruiting
- HIV-1-infection
- Antiretroviral Therapy
- Continuation of boosted PI
- B/F/TAF
-
Port-au-Prince, HaitiGHESKIO
Jul 30, 2020
HIV Trial in United States (Raltegravir (MK-0518), Placebo)
Completed
- HIV Infections
- Raltegravir (MK-0518)
- Placebo
-
Birmingham, Alabama
- +19 more
Nov 2, 2021
Single Versus Double Ritonavir-boosted Protease Inhibitor-Based
Completed
- HIV Infection
- HIV Infections
- ritonavir-boosted PI-based second line treatments
- two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
-
Bangkok, Thailand
- +7 more
Jul 15, 2020
HIV Related Insulin Resistance, Protease Inhibitor Related Insulin Resistance, Endoplasmic Reticulum Stress Trial in Saint Louis
Completed
- HIV Related Insulin Resistance
- +2 more
- Tauroursodeoxycholic acid
- Placebo tablet
-
Saint Louis, MissouriWashington University School of Medicine
Jan 23, 2020
COVID19 Trial in Padova (Nafamostat Mesilate, Placebo)
Recruiting
- COVID19
- Nafamostat Mesilate
- Placebo
-
Padova, ItalyAzienda Ospedale Università di Padova
Jun 4, 2021